Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib open-label study of cevostamab ± pomalidomide/dexamethasone or ± daratumumab/dexamethasone in relapsed/refractory multiple myeloma
jRCT2031230660Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of cevostamab in multiple myeloma (MM) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of cevostamab-based regimens, Pharmacokinetics of cevostamab and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
cevostamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031230660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230660.